Results 21 to 30 of about 1,268 (176)

Ravulizumab and Efgartigimod in Myasthenia Gravis [PDF]

Neurology Neuroimmunology & Neuroinflammation
Finanziert durch den Open-Access-Publikationsfonds der Universität Münster.
Frauke Stascheit, Carla Daiane Ferreira de Sousa, Annette Aigner, Malina Behrens, Christian W. Keller, Luisa Klotz, Sophie Lehnerer, Maike Stein, Meret Herdick, Paolo Doksani, Lea M. Gerischer, Sarah Hoffmann, Konstantinos Lazaridis, John Tzartos, Heinz Wiendl, Andreas Meisel, Jan D. Lünemann   +16 more
openaire   +5 more sources

Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients [PDF]

Frontiers in Neurology
BackgroundEfgartigimod was approved in Japan in January 2022 for the treatment of generalized myasthenia gravis (gMG), regardless of antibody status. This case series describes a real-world experience in Japan of efgartigimod treatment for gMG patients ...
Toshiya Nomura, Michie Imamura, Masao Imura, Hironori Mizutani, Mitsuharu Ueda   +4 more
doaj   +3 more sources

Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report [PDF]

BMC Neurology
Background Anti-NMDA receptor encephalitis is an autoimmune, antibody-mediated inflammatory disease of the brain characterized by the presence of IgG antibodies targeting the excitatory N-methyl-D-aspartate receptor (NMDAR).
Huasheng Huang, Yizhi Wei, Huihui Qin, Guangshun Han, Jie Li   +4 more
doaj   +2 more sources

Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control [PDF]

Biomedicines
Introduction: Myasthenia gravis (MG), an immune disorder affecting nerve-muscle transmission, often necessitates tailored therapies to alleviate longitudinal symptom fluctuations.
Shingo Konno, Takafumi Uchi, Hideo Kihara, Hideki Sugimoto   +3 more
doaj   +2 more sources

Open-label study of efgartigimod in seronegative myasthenia gravis [PDF]

Therapeutic Advances in Neurological Disorders
Background: The ADAPT trial demonstrated the benefit of efgartigimod, a neonatal Fc receptor (FcRn) inhibitor, in acetylcholine receptor antibody (AChRAb) positive patients with generalized myasthenia gravis (MG).
Mohamed Khateb, Ajith Sivadasan, Carolina Barnett-Tapia, Lubna Daniyal, Lahiru Fernando, Shiyi Chen, Leif Erik Lovblom, Hans Katzberg, Vera Bril   +8 more
doaj   +2 more sources

Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series [PDF]

Frontiers in Immunology
IntroductionEfgartigimod is effective and well-tolerated in patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG).
Jie Song, Haiyan Wang, Xiao Huan, Qilong Jiang, Zongtai Wu, Chong Yan, Jianying Xi, Chongbo Zhao, Huiyu Feng, Sushan Luo   +9 more
doaj   +3 more sources

Case Report: Dual response to efgartigimod in myasthenia gravis and comorbid autoimmune disorders: a case series [PDF]

Frontiers in Immunology
The coexistence of myasthenia gravis (MG) with other IgG-mediated autoimmune diseases represents a clinically heterogeneous condition, driven by pathogenic autoantibodies.
Yunjia Li, Yunjia Li, Yunjia Li, Yingying Yang, Yingying Yang, Yingying Yang, Ying Zhu, Ying Zhu, Ying Zhu, Ruixia Zhu, Ruixia Zhu, Ruixia Zhu   +11 more
doaj   +2 more sources

Case Report: A myasthenia gravis patient complicated with renal failure was effectively treated with efgartigimod [PDF]

Frontiers in Immunology
Myasthenia gravis (MG) is a neuromuscular junction disorder clinically characterized by fluctuating muscle weakness, in which some patients with respiratory muscle weakness are at risk of progressing to myasthenia gravis crisis and respiratory failure ...
Jia Ke, Qi Zhao, Na Wang, Bei Zhang, Jin-Quan Hu   +4 more
doaj   +3 more sources

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches [PDF]

Brain and Behavior
Purpose of Review: This review aims to provide a comprehensive analysis of chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on its clinical manifestations, pathophysiology, and treatment advancements, with particular emphasis on ...
Ayesha Khan, Arsal Khan, Kuldeep Dalpat Rai, Anzel Saeed, Harsh Kumar, Aneesh Kumar Sangtiani, Tehreem Fatima, Muhammad Tanveer Alam, Faiza Rajput, Sakshi Chawla, Hussain Haider Shah, Humaira Kalam   +11 more
doaj   +2 more sources

Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single case report [PDF]

Frontiers in Immunology
IntroductionMyasthenia gravis (MG) is an autoimmune disorder primarily affecting the neuromuscular junction. Muscle-specific receptor tyrosine kinase antibody (MuSK-Ab)-mediated MG often presents with bulbar weakness and is prone to crisis.
Xiujun Zheng, Jing Wang, Tongtong Cai, Houshi Zhou   +3 more
doaj   +2 more sources